Atossa Genetics Reports 47% Surge in Short Interest Amid Analyst Ratings Changes

Atossa Genetics Inc. (NASDAQ: ATOS) experienced a significant increase in short interest during December 2023. As of December 15, short interest reached a total of 2,284,050 shares, marking a remarkable growth of 47.0% from the previous total of 1,554,063 shares on November 30. This surge has led to a days-to-cover ratio of 1.6 days, calculated based on an average daily trading volume of 1,461,615 shares. Currently, 1.9% of the company’s shares are sold short.

Analysts have recently weighed in on Atossa Genetics, reflecting varied perspectives on the stock. Ascendiant Capital Markets raised their price target from $7.75 to $8.00 and assigned a “buy” rating in a note published on December 8. Conversely, Zacks Research downgraded the stock from a “hold” to a “strong sell” rating in a report on October 13. Weiss Ratings maintained a “sell (d-)” rating on October 8. Overall, one analyst has issued a Strong Buy rating, two have given a Buy rating, and two have assigned a Sell rating. According to MarketBeat.com, Atossa Genetics has a consensus rating of “Hold” with an average price target of $6.33.

Current Market Performance and Financial Outlook

As of Wednesday, December 20, Atossa Genetics shares opened at $0.62, reflecting a decline of 5.6%. The company has a market capitalization of $80.28 million and a price-to-earnings ratio of -2.59. Over the past year, the stock has fluctuated between a low of $0.55 and a high of $1.29. The firm’s 50-day and 200-day simple moving averages stand at $0.79 and $0.83, respectively.

Atossa Genetics last reported its quarterly earnings on November 12, posting earnings per share of ($0.07), in line with analysts’ expectations. Looking ahead, analysts project that the company will report earnings of ($0.22) per share for the current fiscal year.

Company Overview and Research Pipeline

Based in Seattle, Washington, Atossa Genetics is a clinical-stage biotechnology company focused on developing therapeutics and diagnostic products for breast cancer and related conditions. The company aims to deliver targeted, minimally invasive solutions for early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

Atossa’s pipeline includes Z-Endoxifen, an oral formulation aimed at treating and preventing estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence. The company continues to make strides in its mission to address critical needs in breast cancer care.

As investors and analysts monitor Atossa Genetics, the developments in short interest and shifting analyst ratings will be pivotal in shaping the company’s market trajectory and investor sentiment.